1. Home
  2. CDT vs JAGX Comparison

CDT vs JAGX Comparison

Compare CDT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • JAGX
  • Stock Information
  • Founded
  • CDT 2019
  • JAGX 2013
  • Country
  • CDT United States
  • JAGX United States
  • Employees
  • CDT N/A
  • JAGX N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CDT Health Care
  • JAGX Health Care
  • Exchange
  • CDT Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • CDT 11.1M
  • JAGX 12.9M
  • IPO Year
  • CDT N/A
  • JAGX N/A
  • Fundamental
  • Price
  • CDT $1.15
  • JAGX $0.86
  • Analyst Decision
  • CDT
  • JAGX
  • Analyst Count
  • CDT 0
  • JAGX 0
  • Target Price
  • CDT N/A
  • JAGX N/A
  • AVG Volume (30 Days)
  • CDT 8.8M
  • JAGX 311.0K
  • Earning Date
  • CDT 03-04-2025
  • JAGX 03-31-2025
  • Dividend Yield
  • CDT N/A
  • JAGX N/A
  • EPS Growth
  • CDT N/A
  • JAGX N/A
  • EPS
  • CDT N/A
  • JAGX N/A
  • Revenue
  • CDT N/A
  • JAGX $10,480,000.00
  • Revenue This Year
  • CDT N/A
  • JAGX $18.18
  • Revenue Next Year
  • CDT N/A
  • JAGX $40.06
  • P/E Ratio
  • CDT N/A
  • JAGX N/A
  • Revenue Growth
  • CDT N/A
  • JAGX N/A
  • 52 Week Low
  • CDT $1.13
  • JAGX $0.78
  • 52 Week High
  • CDT $392.00
  • JAGX $21.60
  • Technical
  • Relative Strength Index (RSI)
  • CDT 31.53
  • JAGX 45.91
  • Support Level
  • CDT $1.60
  • JAGX $0.78
  • Resistance Level
  • CDT $3.70
  • JAGX $1.03
  • Average True Range (ATR)
  • CDT 0.44
  • JAGX 0.07
  • MACD
  • CDT 0.09
  • JAGX 0.01
  • Stochastic Oscillator
  • CDT 0.78
  • JAGX 30.44

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: